# EDGAR Filing Document

**Accession Number:** 0001681682
**File Stem:** 0001213900-26-057757
**Filing Date:** 2026-5
**Character Count:** 37212
**Document Hash:** 777aba3e7fff915aa28ec04c8bc3eb5c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-057757.hdr.sgml**: 20260515

**ACCESSION NUMBER**: 0001213900-26-057757

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260515

**DATE AS OF CHANGE**: 20260515

**EFFECTIVENESS DATE**: 20260515

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ENDRA Life Sciences Inc.
- **CENTRAL INDEX KEY:** 0001681682
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 260579295
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295947
- **FILM NUMBER:** 26987585

**BUSINESS ADDRESS:**
- **STREET 1:** 3600 GREEN COURT
- **STREET 2:** SUITE 350
- **CITY:** ANN ARBOR
- **STATE:** MI
- **ZIP:** 48105
- **BUSINESS PHONE:** 734-335-0468

**MAIL ADDRESS:**
- **STREET 1:** 3600 GREEN COURT
- **STREET 2:** SUITE 350
- **CITY:** ANN ARBOR
- **STATE:** MI
- **ZIP:** 48105

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Endra Inc.
- **DATE OF NAME CHANGE:** 20160805

As filed with the Securities and Exchange Commission on May 15, 2026

Registration No. 333-

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933** 

---

| |
|:---|
| **ENDRA LIFE SCIENCES INC.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **Delaware** | **26-0579295** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| **3600 Green Court, Suite 350**<br> **Ann Arbor, MI** | **48105** |
| (Address of principal executive offices) | (Zip Code) |

---

**ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan, as amended**

(Full title of the plan)

**Alexander Tokman**

**Chief Executive Officer**

**ENDRA Life Sciences Inc.**

**3600 Green Court, Suite 350**

**Ann Arbor, MI 48105**

(Name and address of agent for service)

**(734) 335-0468**

(Telephone number, including area code,

of agent for service)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed by ENDRA Life Sciences Inc. (the "Company") to register an additional 3,200,000 shares of Common Stock under the Company's 2016 Omnibus Incentive Plan, as amended (the "Plan"), as a result of the stockholders of the Company approving an amendment to the Plan to increase the number of shares of common stock available for issuance thereunder at the Company's 2025 annual meeting of stockholders held on December 9, 2025.

These additional shares of Common Stock are securities of the same class as other securities for which the Registration Statements on Form S-8 (File Nos. [333-218894](https://www.sec.gov/Archives/edgar/data/1681682/000165495417005772/end_s8.htm), [333-233178](https://www.sec.gov/Archives/edgar/data/1681682/000165495419009167/ndra_s8.htm), [333-237415](https://www.sec.gov/Archives/edgar/data/1681682/000165495420003349/ndra_s8.htm), [333-254713](https://www.sec.gov/Archives/edgar/data/1681682/000165495421003304/ndra_s8.htm), [333-263992](https://www.sec.gov/Archives/edgar/data/1681682/000165495422004174/endra_s8.htm), [333-270616](https://www.sec.gov/Archives/edgar/data/1681682/000165495423003045/endra_s8.htm), [333-278346](https://www.sec.gov/Archives/edgar/data/1681682/000165495424003885/endra_s8.htm), and [333-286344](https://www.sec.gov/Archives/edgar/data/1681682/000165495425003848/endra_s8.htm)) (the "Prior Registration Statements") were filed with the Securities and Exchange Commission (the "Commission") on June 21, 2017, August 9, 2019, March 26, 2020, March 25, 2021, March 30, 2022, March 16, 2023, March 28, 2024, and April 2, 2025, respectively. In accordance with Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made a part of this Registration Statement on Form S-8.

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

**Item 1. Plan Information.** 

The information required by this Item 1 is omitted from this registration statement in accordance with Rule 428(b)(1) of the Securities Act of 1933, as amended (the "Securities Act"), and the Note to Part I of Form S-8.

**Item 2. Registrant Information and Employee Plan Annual Information.** 

The information required by this Item 2 is omitted from this registration statement in accordance with Rule 428(b)(1) of the Securities Act and the Note to Part I of Form S-8.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.** 

The following documents have been filed by ENDRA Life Sciences Inc. (the "Registrant") with the Commission and are incorporated herein by reference:

● Annual Report on [Form 10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1681682/000121390026037617/ea0283994-10k_endra.htm) for the fiscal year ended December 31, 2025, filed with the Commission on March 31, 2026;

● Quarterly Report on [Form 10-Q](https://www.sec.gov/ix?doc=/Archives/edgar/data/1681682/000121390026057680/ea0290744-10q_endra.htm) the quarter ended March 31, 2026, filed with the Commission on May 15, 2026;

● Current Reports on Form 8-K filed with the Commission on [March 25, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/1681682/000121390026033878/ea0283331-8k_endra.htm) and [April 21, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/1681682/000121390026045885/ea0287103-8k_endra.htm) ; and

● The description of the Registrant's Common Stock contained in the Registrant's Registration Statement on [Form S-1](http://www.sec.gov/Archives/edgar/data/1681682/000165495416004197/end_drs.htm) , originally filed with the Commission on November 21, 2016, as amended (File No. 333-214724), which description is incorporated by reference into the Registrant's Registration Statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1681682/000165495416004941/end_8a12b.htm) , originally filed with the Commission pursuant to Section 12(g) of the Exchange Act on December 16, 2016 (File No. 001-37969), including any further amendment or report filed hereafter for the purpose of updating such description.

All reports and other documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date hereof, and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents. The Registrant is not incorporating by reference any reports or documents or portions thereof that are not considered to be "filed" with the Commission.

Any statement contained herein or in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated herein by reference modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 6. Indemnification of Directors and Officers.**

The following summary is qualified in its entirety by reference to the complete text of any statutes referred to below and the Registrant's Fourth Amended and Restated Certificate of Incorporation.

Section 145 of the DGCL, or Section 145, provides that a Delaware corporation may indemnify any person who was, is or is threatened to be made, party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such person is or was an officer, director, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation's best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was illegal. A Delaware corporation may indemnify any persons who were or are a party to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is or was a director, officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys' fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit, provided such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation's best interests, provided that no indemnification is permitted without judicial approval if the officer, director, employee or agent is adjudged to be liable to the corporation. Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation must indemnify him or her against the expenses which such officer or director has actually and reasonably incurred.

Section 145 further authorizes a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against any liability asserted against him and incurred by him in any such capacity, or arising out of his or her status as such, whether or not the corporation would otherwise have the power to indemnify him under Section 145.

Section 102(b)(7) of the DGCL allows a corporation to provide in its certificate of incorporation that a director of the corporation will not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except where the director breached the duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The Company's Certificate of Incorporation provides for this limitation of liability. Article NINTH of our Fourth Amended and Restated Certificate of Incorporation states that our directors shall not be personally liable to us or to our stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability.

Article EIGHTH of our Fourth Amended and Restated Certificate of Incorporation provides that we shall indemnify (and advance expenses to) our officers and directors to the full extent permitted by the DGCL.

All of the Company's directors and officers are covered by insurance policies maintained by the Company against specified liabilities for actions taken in their capacities as such, including liabilities under the Securities Act. Such insurance also insures us against losses which we may incur in indemnifying our officers and directors.

As permitted by the DGCL, we have entered into indemnification agreements with each of our directors and executive officers that require us to indemnify them against various actions including, but not limited to, third-party actions where such director or executive officer, by reason of his or her corporate status, is a party or is threatened to be made a party to an action, or by reason of anything done or not done by such director in any such capacity. We indemnify directors and executive officers against all costs, judgments, penalties, fines, liabilities, amounts paid in settlement by or on behalf of such directors or executive officers and for any expenses actually and reasonably incurred by such directors or executive officers in connection with such action, if such directors or executive officers acted in good faith and in a manner they reasonably believed to be in or not opposed to our best interests, and with respect to any criminal proceeding, had no reasonable cause to believe their conduct was unlawful. We also intend to advance to our directors and executive officers expenses (including attorney's fees) incurred by or on behalf of such directors and executive officers in advance of the final disposition of any action after our receipt of a statement or statements from directors or executive officers requesting such payment or payments from time to time, provided that such statement or statements are preceded or accompanied by a written undertaking, by or on behalf of such directors or executive officers, to repay such amount if it shall ultimately be determined that they are not entitled to be indemnified against such expenses by us.

The indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification or advancement of expenses, including, among others, provisions about submitting a written request to us that includes such documentation and information as is reasonably available to the director or executive officer and is reasonably necessary to determine entitlement to indemnification and provisions.

**Item 7. Exemption from Registration Claimed.**

Not applicable.

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 4.1 | [Fourth Amended and Restated Certificate of Incorporation of ENDRA Life Sciences Inc., as amended (incorporated by reference to Exhibit 3.1 to the Registrant's Annual Report on Form 10-K filed on March 31, 2026)](https://www.sec.gov/Archives/edgar/data/1681682/000121390026037617/ea028399401ex3-1.htm) |
| <u>4.2</u> | [Amended and Restated Bylaws of ENDRA Life Sciences Inc. (incorporated by reference to Exhibit 3.4 to Amendment No. 1 to the Registrant's Registration Statement on Form S-1 (File No. 333-214724) filed on December 6, 2016)](http://www.sec.gov/Archives/edgar/data/1681682/000165495416004599/end_ex34.htm) |
| 4.3 | [ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.4 to Amendment No. 1 to the Registrant's Registration Statement on Form S-1 (File No. 333-214724) filed on December 6, 2016)](http://www.sec.gov/Archives/edgar/data/1681682/000165495416004599/end_ex104.htm) |
| 4.4 | [First Amendment to ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan (incorporated by reference to Appendix A to the Registrant's Definitive Proxy Statement filed on May 10, 2018)](http://www.sec.gov/Archives/edgar/data/1681682/000121390018005842/def14a061218_endralife.htm) |
| 4.5\* | [Second Amendment to ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan](ea028407601ex4-5.htm) |
| 4.6 | [Form of Stock Option Award under ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.5 to Amendment No. 1 to the Registrant's Registration Statement on Form S-1 (File No. 333-214724) filed on December 6, 2016)](http://www.sec.gov/Archives/edgar/data/1681682/000165495416004599/end_ex105.htm) |
| 4.7 | [Form of Restricted Stock Unit Award under ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.6 to Amendment No. 1 to the Registrant's Registration Statement on Form S-1 (File No. 333-214724) filed on December 6, 2016)](http://www.sec.gov/Archives/edgar/data/1681682/000165495416004599/end_ex106.htm) |
| 5.1\* | [Opinion of K&L Gates LLP](ea028407601ex5-1.htm) |
| 23.1\* | [Consent of RBSM LLP, Independent Registered Public Accounting Firm](ea028407601ex23-1.htm) |
| 23.2 | [Consent of K&L Gates LLP (contained in Exhibit 5.1)](ea028407601ex5-1.htm) |
| 24.1 | [Power of Attorney (included on the signature page of this Registration Statement)](#pob_001) |
| 107.1\* | [Filing Fee Table](ea028407601ex-fee.htm) |

---

\* - Filed herewith

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Ann Arbor, State of Michigan, on May 15, 2026.

---

| | |
|:---|:---|
| ENDRA Life Sciences Inc. | ENDRA Life Sciences Inc. |
| By: | /s/ Alexander Tokman |
|  | Alexander Tokman |
|  | Chief Executive Officer |

---

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints Alexander Tokman and Richard Jacroux, and each of them, his/her true and lawful attorney-in-fact and agent, each with full power of substitution and resubstitution, severally, for him/her and in his/her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he/she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney may be executed in counterparts.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities indicated, in each case on May 15, 2026:

---

| | |
|:---|:---|
| **Signature** | **Title** |
| /s/ Alexander Tokman | Acting Chief Executive Officer and Director |
| Alexander Tokman | (Principal Executive Officer) |
| /s/ Richard Jacroux | Chief Financial Officer |
| Richard Jacroux | (Principal Financial Officer and Principal Accounting Officer) |
| /s/ Louis J. Basenese | Director |
| Louis J. Basenese |  |
| /s/ Anthony DiGiandomenico | Director |
| Anthony DiGiandomenico |  |
| /s/ Michael Harsh | Director |
| Michael Harsh |  |

---

## Exhibit 4.5

**Exhibit 4.5**

**Second Amendment to ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan**

This Second Amendment, dated December 9, 2025 (the "<u>Amendment</u>"), to the 2016 Omnibus Incentive Plan, as amended (the "<u>Existing Plan</u>"; as amended hereby, the "<u>Plan</u>"), of ENDRA Life Sciences Inc., a Delaware corporation (the "<u>Company</u>"), is made and adopted by the Company, subject to approval of the stockholders of the Company (the "<u>Stockholders</u>"). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Plan.

<u>Statement of Purpose</u>

The Existing Plan was originally approved by the Company's Board of Directors (the "<u>Board</u>") and the Stockholders in 2018. The Board may amend the Existing Plan at any time, pursuant to and subject to <u>Section 5.2</u> of the Existing Plan, contingent on approval by the Stockholders if the Stockholders' approval is required by applicable securities exchange rules or applicable law. The Board has determined that it is advisable and in the best interest of the Company to amend the Existing Plan to provide for an annual increase in the number of Shares authorized for issuance under the Plan.

NOW, THEREFORE, the Existing Plan is hereby amended as follows, subject to approval by the Stockholders:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Amendment to Section 4.1 of Existing Plan</u>. <u>Section 4.1</u> of the Existing Plan is hereby deleted in its entirety and replaced with the following:

"**4.1. Authorized Number of Shares**

Subject to adjustment under **Section 15**, the aggregate number of Shares that may be issued pursuant to the Plan following Stockholder approval of the Plan shall equal 3,379,474; *provided, however*, that on each January 1 beginning in 2019, the number of Shares authorized to be issued under the Plan shall be increased by an amount equal to the lesser of (i) the number of Shares necessary such that the aggregate number of Shares available to be issued under the Plan equals 25% of the number of fully diluted outstanding Shares on the increase date (assuming the conversion of all outstanding shares of preferred stock and other outstanding convertible securities and exercise of all outstanding options and warrants to purchase Shares) and (ii) if the Board takes action to set a lower amount, the amount determined by the Board. Shares issued under the Plan may consist in whole or in part of authorized but unissued Shares, treasury Shares, or Shares purchased on the open market or otherwise.

Notwithstanding the foregoing, the maximum number of Shares available for issuance under Incentive Stock Options under the Plan shall be 3,379,474."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Reference to and Effect on the Plan</u>. The Plan, as amended hereby, and all other documents, instruments, and agreements executed and/or delivered in connection therewith, shall remain in full force and effect, and are hereby ratified and confirmed.

## Exhibit 5.1

**Exhibit 5.1**

![](ea028407601_ex5-1img1.jpg)

May 15, 2026

ENDRA Life Sciences Inc.

3600 Green Court, Suite 350

Ann Arbor, MI 48105

Ladies and Gentlemen:

We have acted as special counsel to ENDRA Life Sciences Inc., a Delaware corporation (the "<u>Company</u>"), in connection with the Registration Statement on Form S-8 (the "<u>Registration Statement</u>") to be filed by the Company on the date hereof with the Securities and Exchange Commission (the "<u>Commission</u>") under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), and the rules and regulations promulgated thereunder, for the registration of 3,200,000 shares (collectively, the "<u>Shares</u>" and each, a "<u>Share</u>") of common stock, par value $0.0001 per share, of the Company ("<u>Common Stock</u>"), issuable pursuant to the Second Amendment to ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan, dated December 9, 2025 (the "<u>Second Amendment</u>"), which Second Amendment amended the ENDRA Life Sciences Inc. 2016 Omnibus Incentive Plan (the "<u>Original Plan</u>"), as amended by the First Amendment thereto dated May 7, 2018 (the "<u>First Amendment</u>" and the Original Plan, as amended by the First Amendment and the Second Amendment, the "<u>Plan</u>").

You have requested our opinion as to the matters set forth below in connection with the Registration Statement. For purposes of rendering that opinion, we have examined: (a) the Registration Statement; (b) the Fourth Amended and Restated Certificate of Incorporation of the Company as filed with the Secretary of State of the State of Delaware (the "<u>Secretary of State</u>") on May 9, 2017, as amended by the Certificate of Designations of Series A Convertible Preferred Stock of the Company as filed with the Secretary of State on December 12, 2019, the Certificate of Designation of Series B Convertible Preferred Stock of the Company as filed with the Secretary of State on December 23, 2019, the Certificate of Amendment of Certificate of Incorporation of the Company as filed with the Secretary of State on June 17, 2020, the Certificate of Designation of Series C Preferred Stock of the Company as filed with the Secretary of State on September 27, 2022, the Certificate of Amendment of Certificate of Incorporation as filed with the Secretary of State on December 8, 2022, the Certificate of Amendment of Certificate of Incorporation as filed with the Secretary of State on August 8, 2024, the Certificate of Amendment of Certificate of Incorporation as filed with the Secretary of State on August 16, 2024, the Certificate of Amendment of Certificate of Incorporation as filed with the Secretary of State on November 4, 2024, and the Certificate of Amendment of Certificate of Incorporation as filed with the Secretary of State on December 10, 2025; (c) the Amended and Restated Bylaws of the Company adopted on December 19, 2016; (d) the Plan; (e) the resolutions adopted by the Board of Directors of the Company (the "<u>Board of Directors</u>") at a meeting of the Board of Directors held on November 16, 2016 approving the Original Plan; (f) the resolutions adopted by the stockholders of the Company by consent in lieu of a meeting effective as of December 5, 2016 approving the Original Plan; (g) the resolutions adopted by the Compensation Committee of the Board of Directors of the Company (the "<u>Compensation Committee</u>") by unanimous consent in lieu of a meeting of the Compensation Committee effective as of November 14, 2025 approving the Second Amendment and the increase in the number of shares of Common Stock available for issuance pursuant to the Original Plan, as amended by the First Amendment, by 3,200,000 shares of Common Stock; (h) the resolutions adopted by the Board of Directors by unanimous consent in lieu of a meeting of the Board of Directors effective as of November 14, 2025 approving the Second Amendment and the increase in the number of shares of Common Stock available for issuance pursuant to the Original Plan, as amended by the First Amendment, by 3,200,000 shares of Common Stock; (i) the minutes of the 2025 annual meeting of stockholders of the Company held on December 9, 2025 reflecting that the Second Amendment was approved; and (j) a certificate of an officer of the Company, dated as of the date hereof. Other than our review of the documents listed in (a) through (j) above (collectively, the "<u>Reviewed Documents</u>"), we have not reviewed any other documents or made any independent investigation for the purpose of rendering this opinion.

ENDRA Life Sciences Inc.

May 15, 2026

For purposes of rendering our opinion below, we have not reviewed any document other than the Reviewed Documents and assume there exists no provision in any document relating to the matters covered by our opinion below that we have not reviewed that is inconsistent with the Reviewed Documents or our opinion below. We have conducted no independent factual investigation of our own but rather have relied on the Reviewed Documents, the statements and information set forth therein and the additional matters recited or assumed herein, all of which we assume to be true, complete, and accurate in all respects.

For purposes of this opinion letter, we have made assumptions that are customary in opinion letters of this kind, including the assumptions that: (i) each of the Reviewed Documents is accurate and complete; (ii) each of the Reviewed Documents that is an original is authentic; (iii) each Reviewed Document that is a copy conforms to an authentic original; (iv) there are no documents other than the Reviewed Documents that could affect the opinion expressed in this opinion letter and no amendments, modifications, or waivers of the Reviewed Documents; (v) all signatures on each of the Reviewed Documents are genuine; (vi) all of the Reviewed Documents were duly executed and delivered where due execution and delivery are prerequisites to the effectiveness thereof; and (vii) the Company is and shall remain at all times a corporation duly incorporated, validly existing, and in good standing under the laws of the State of Delaware. We have further assumed: (i) the legal capacity of natural persons; (ii) that each party to the Reviewed Documents (A) has the legal capacity, power, and authority to execute, deliver, and perform its obligations under the Reviewed Documents to which it is a party, (B) is duly formed or incorporated, as applicable, organized, validity existing, and in good standing under the laws of its formation or incorporation, as applicable, and (C) has taken all actions necessary to authorize the execution and delivery of, and the performance of such party's obligations under, the Reviewed Documents to which it's a party; (iii) that any amendment and/or restatement of any of the Reviewed Documents was accomplished in accordance with, and was permitted by, the relevant provisions of such document and applicable law; (iv) that each of the Reviewed Documents constitute the legal, valid, and binding obligation of each party thereto, enforceable against each such part in accordance with its terms; and (v) that the issuance of the Shares will not increase the proportionate share of Common Stock held by an "interested stockholder" (within the meaning of Section 203(c) of the General Corporation Law of the State of Delaware (the "<u>DGCL</u>")). We have not verified any of the foregoing assumptions.

In rendering our opinion below, we also have assumed that: (i) the Company will have sufficient authorized, unissued, and unreserved shares of Common Stock at the time of each issuance of a Share or any right or option to acquire a Share, in each case, under the Plan; (ii) either (A) upon the issuance of a Share, such Share will be evidenced by a certificate that has been duly executed and delivered, or (B) the Board of Directors of the Company (the "<u>Board</u>") has adopted a resolution (that has not been rescinded or revoked) providing that all shares of Common Stock shall be uncertificated in accordance with Section 158 of the DGCL prior to the issuance of such Share and, within a reasonable time after the issuance of such uncertificated Share, the registered owner of such Share will be given notice in writing or by electronic transmission in compliance with Section 151(f) of the DGCL; (iii) the issuance of each Share will be duly recorded in the Company's stock ledger upon its issuance; (iv) the Plan and each Award Agreement (as defined in the Plan) in the form approved by the Board of Directors (such Award Agreement, hereinafter referred to as an "<u>Award Agreement</u>") constitutes or will constitute, as applicable, the valid and binding agreement of the Company, enforceable against the Company in accordance with its terms; (v) the Company will receive consideration for each Share as set forth in the Authorizing Resolutions (as defined below), which consideration shall be at least equal to the par value of such share of Common Stock (unless such Share is held in treasury, in which case, the consideration shall be the amount, as set forth in the Authorizing Resolutions), and, in the amount required by the Plan and the applicable Award Agreement; (vi) with respect to any Shares issuable upon the exercise of any right or option to acquire Shares under the Plan, the Company shall have received the minimum consideration for which such rights or options may be issued pursuant to the Authorizing Resolutions, the Plan, and the applicable Award Agreement; and (vii) prior to the issuance of any Shares (or any right or option to acquire any Shares) under the Plan, the Board (or a duly authorized or subcommittee committee thereof) will duly authorize each Award (as defined in the Plan) granted under the Plan with respect to which Shares are issued pursuant to an Award Agreement and in accordance with the DGCL and the Plan (the "<u>Authorizing Resolutions</u>"). We have not verified any of the foregoing assumptions.

ENDRA Life Sciences Inc.

May 15, 2026

Our opinion set forth below is limited to the DGCL and reported judicial decisions interpreting the DGCL. We express no opinion as to the laws, rules or regulations of any other jurisdiction, including, without limitation, the federal laws of the United States of America or any state securities or blue sky laws; we express no opinion with respect to the Corporate Transparency Act.

Based upon and subject to the foregoing and assuming that the Registration Statement is effective at the time of issuance of the Shares, it is our opinion that the Shares (a) are duly authorized for issuance by the Company pursuant to, and on the terms set forth in, the Plan and, (b) when and if issued and paid for in accordance with the terms of the Plan, the Authorizing Resolutions, and the applicable Award Agreement, will be validly issued, fully paid, and non-assessable.

This opinion is expressed as of the date hereof, and we disclaim any undertaking to advise you of any subsequent changes in the facts stated or assumed herein or of any subsequent changes in applicable laws.

We hereby consent to the filing of this opinion letter with the Commission as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

---

| |
|:---|
| Yours truly, |
| /s/ K&L Gates LLP |
| K&L Gates LLP |

---

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 31, 2026 on the consolidated financial statements of ENDRA Life Sciences Inc. and its subsidiaries, appearing in the annual report on Form 10-K of ENDRA Life Sciences Inc. for the year ended December 31, 2025. Our report includes an explanatory paragraph expressing substantial doubt regarding the Company's ability to continue as a going concern.

/s/ RBSM LLP

Houston, Texas

May 15, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**ENDRA Life Sciences Inc.**

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common Stock, $0.0001 par value per share, to be issued under the Registrant's 2016 Omnibus Incentive Plan | (1) | Other | 3200000 | $5.0325 | $16104000.00 | 0.0001381 | $2223.97 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $16104000.00 |  | 2223.97 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $2223.97 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) 1a. Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers such indeterminate number of additional shares of the Registrant's common stock ("Common Stock") as is necessary to eliminate any dilutive effect of any future stock split, stock dividend or similar transaction. 1b. Proposed Maximum Offering Price Per Unit is estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act and based on the average of the high and low prices for the Registrant's Common Stock on May 11, 2026, as reported on The Nasdaq Capital Market. 1c. Represents 3,200,000 additional shares of Common Stock reserved for future issuance under the Registrant's 2016 Omnibus Incentive Plan, as amended by the Second Amendment effective December 9, 2025.